Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a report published on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $30.00 price objective on the stock.

A number of other equities research analysts also recently commented on the company. Jones Trading assumed coverage on Definium Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Royal Bank Of Canada upped their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Canaccord Genuity Group increased their price objective on shares of Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Finally, Robert W. Baird set a $37.00 price target on shares of Definium Therapeutics in a research report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Definium Therapeutics currently has a consensus rating of “Buy” and an average price target of $35.22.

Definium Therapeutics Stock Down 2.1%

Definium Therapeutics stock opened at $16.88 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The firm has a 50 day moving average price of $13.76 and a 200 day moving average price of $11.76. The company has a market capitalization of $1.66 billion, a PE ratio of -8.27 and a beta of 2.57. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.12.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.26). Research analysts expect that Definium Therapeutics will post -1.35 earnings per share for the current year.

Insider Buying and Selling at Definium Therapeutics

In related news, insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the sale, the insider directly owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. This represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the transaction, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 42,667 shares of company stock valued at $561,071 over the last ninety days. Corporate insiders own 2.26% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Palumbo Wealth Management LLC boosted its holdings in Definium Therapeutics by 18.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock valued at $522,000 after purchasing an additional 6,073 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Definium Therapeutics during the 4th quarter valued at approximately $117,000. Bay Rivers Group grew its position in shares of Definium Therapeutics by 14.3% during the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after buying an additional 2,000 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Definium Therapeutics in the third quarter worth $107,000. Finally, Caxton Associates LLP bought a new stake in shares of Definium Therapeutics in the third quarter worth $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.